Mesothelin and MUC16 (CA125) Are Antigen-Targets for CAR T-Cell Therapy in Primary and Metastatic Lung Adenocarcinoma

被引:0
|
作者
Eguchi, Takashi [1 ]
Ujiie, Hideki [1 ]
Morello, Aurore [2 ,3 ]
Kadota, Kyuichi [4 ]
Buitrago, Daniel H. [1 ]
Woo, Kaitlin [5 ]
Jones, David R. [1 ]
Travis, William D. [6 ]
Sadelain, Michel [3 ]
Adusumilli, Prasad S. [2 ,3 ]
机构
[1] Mem Sloan Kettering Canc, Dept Surg, Thorac Serv, New York, NY USA
[2] Mem Sloan Kettering Canc, Thorac Serv, New York, NY USA
[3] Mem Sloan Kettering Canc, Ctr Cell Engn, New York, NY USA
[4] Kagawa Univ, Dept Diagnost Pathol, Takamatsu, Kagawa 760, Japan
[5] Mem Sloan Kettering Canc, Dept Epidemiol & Biostat, New York, NY USA
[6] Mem Sloan Kettering Canc, Dept Pathol, New York, NY USA
关键词
MUC16; mesothelin; Immunotherapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ORAL28.05
引用
收藏
页码:S229 / S229
页数:1
相关论文
共 50 条
  • [31] MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma
    Sotoudeh, Masoud
    Shirvani, Seyed Iman
    Merat, Shahin
    Ahmadbeigi, Naser
    Naderi, Mahmood
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (04) : 5010 - 5017
  • [32] Identification of a Mu-9 (anti-colon-specific antigen-p)-reactive peptide having homology to CA125 (MUC16)
    Modrak, DE
    Karacay, H
    Cardillo, TM
    Newsome, G
    Goldenberg, DM
    Gold, DV
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 26 (06) : 1591 - 1596
  • [33] NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of potent payload by counteracting MUC16/CA125 effects
    Grasso, Luigi
    Kline, J. Bradford
    Nicolaides, Nicholas C.
    CANCER RESEARCH, 2023, 83 (07)
  • [34] NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects
    Nicolaides, Nicholas C. C.
    Kline, J. Bradford
    Grasso, Luigi
    PLOS ONE, 2023, 18 (05):
  • [35] Mechanistic Insights into CAR T-Cell Efficacy in the Treatment of Heterogenous Antigen Expressing Lung Adenocarcinoma
    Morello, Aurore
    Zeltsman, Masha
    Bograd, Adam
    Jones, David
    Adusumilli, Prasad
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S363 - S364
  • [36] Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies
    Goodell, Cara A. R.
    Belisle, Jennifer A.
    Gubbels, Jennifer A. A.
    Migneault, Martine
    Rancourt, Claudine
    Connor, Joseph
    Kunnimalaiyaan, Muthusamy
    Kravitz, Rachel
    Tucker, Ward
    Zwick, Michael
    Patankar, Manish S.
    JOURNAL OF OVARIAN RESEARCH, 2009, 2 (01):
  • [37] Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies
    Cara AR Goodell
    Jennifer A Belisle
    Jennifer AA Gubbels
    Martine Migneault
    Claudine Rancourt
    Joseph Connor
    Muthusamy Kunnimalaiyaan
    Rachel Kravitz
    Ward Tucker
    Michael Zwick
    Manish S Patankar
    Journal of Ovarian Research, 2
  • [38] NAV-006: A next-generation rituximab targeting CD20 for the treatment of B-cell lymphomas immunosuppressed by MUC16/CA125
    Grasso, Luigi
    Kline, J. Bradford
    Nicolaides, Nicholas C.
    CANCER RESEARCH, 2024, 84 (06)
  • [39] Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days
    Mikkilineni, Lekha
    Yates, Bonnie
    Steinberg, Seth M.
    Shahani, Shilpa A.
    Molina, John C.
    Palmore, Tara
    Lee, Daniel W.
    Kaplan, Rosandra N.
    Mackall, Crystal L.
    Fry, Terry J.
    Gea-Banacloche, Juan
    Jerussi, Theresa
    Nussenblatt, Veronique
    Kochenderfer, James N.
    Shah, Nirali N.
    BLOOD ADVANCES, 2021, 5 (23) : 5312 - 5322
  • [40] Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1
    Mun, Sung Soo
    Meyerberg, Jeremy
    Peraro, Leila
    Korontsvit, Tatyana
    Gardner, Thomas
    Malviya, Manish
    Kyi, Chrisann
    O'Cearbhaill, Roisin E.
    Liu, Cheng
    Dao, Tao
    Scheinberg, David A.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (11) : 3773 - 3786